Table 1. Clinicopathological features of patients with ESCC.
| Characteristics | Stable group (%) (n=11 patients) |
Relapsed group (%) (n=12 patients) |
P value |
|---|---|---|---|
| Sex | 0.193 | ||
| Male | 6 (54.5%) | 10 (83.3%) | |
| Female | 5 (45.5%) | 2 (16.7%) | |
| Age | 1.000 | ||
| ≤65 | 7 (63.6%) | 7 (58.3%) | |
| >65 | 4 (36.4%) | 5 (41.7%) | |
| Pathological grade | 0.539 | ||
| G1/G1–2 | 2 (18.2%) | 4 (33.3%) | |
| G2/G2–3 | 4 (36.4%) | 5 (41.7%) | |
| G3 | 5 (45.5%) | 3 (25.0%) | |
| T classification | 0.667 | ||
| T1/T2 | 3 (27.3%) | 5 (41.7%) | |
| T3 | 8 (72.7%) | 7 (58.3%) | |
| N classification | 0.684 | ||
| N0 | 6 (54.5%) | 5 (41.7%) | |
| N1–3 | 5 (45.5%) | 7 (58.3%) | |
| Clinical stage | 1.000 | ||
| I | 1 (9.1%) | 1 (8.3%) | |
| II | 5 (45.5%) | 5 (41.7%) | |
| III | 5 (45.5%) | 6 (50.0%) | |
| Radiation dose | 1.000 | ||
| 45–50 Gy | 6 (54.5%) | 7 (58.3%) | |
| >50 Gy | 5 (45.5%) | 5 (41.7%) | |
| Adjuvant chemotherapy | 1.000 | ||
| Yes | 6 (54.5%) | 7 (58.3%) | |
| No | 5 (45.5%) | 5 (41.7%) |
Fisher’s exact test. Values of P≤0.05 show statistically significant differences. ESCC, esophageal squamous cell carcinoma.